PFS Benefit in NSCLC Immunotherapy Predicted With Liquid Biopsy for Mutation Burden – Targeted Oncology
Targeted Oncology |
PFS Benefit in NSCLC Immunotherapy Predicted With Liquid Biopsy for Mutation Burden
Targeted Oncology Tumor mutation burden in blood (bTMB) ≥16 had a significant association with improved progression-free survival (PFS) in patients treated with the PD-L1 inhibitor atezolizumab (Tecentriq), according to findings reported at the 2017 ESMO Congress. |
